SARS-CoV
SARS coronavirus
SARS-CoV is the coronavirus (CoV) that causes severe acute respiratory syndrome (SARS). CoVs are enveloped viruses with a positive-sense, single-stranded RNA and can cause health-threatening outbreaks by targeting human respiratory system, including not only SARS, but also Middle East respiratory syndrome (MERS) and SARS-CoV-2 (the cause of COVID-19).
CoVs have four main structural proteins: spike(S), membrane (M), envelope (E), and nucleocapsid (N) proteins. An S protein mediates the CoV entry into host cells by attaching to a cellular receptor (ACE2 for SARS-CoV and SARS-CoV-2, DPP4 for MERS-CoV), followed by fusion between virus and host cell membranes. Genome replication and subgenomic RNA transcription after entry carry on with the participation of many nonstructural proteins such as Mpro (main protease or 3CLpro), PLpro (papain-like protease) and RdRp (RNA-dependent RNA polymerase). Then the structural proteins are translated, assembled into mature virions, and released via vesicles by exocytosis. It is worth mentioning that a protease called TMPRSS2 (transmembrane protease, serine 2) play important roles throughout the whole life of CoVs (such as attachment, assembling and release) by cleaving S protein. All the proteins and subcellular structures participated in the life cycle of CoVs are promising targets for treatment of disease caused by CoVs.
All Product Categories
-
SARS-CoV Related Products (1184)
Related Products (1184)
-
Recombinant Proteins (195)
-
HR2-18
0 ImagesCat. No.: HY-P5398CAS No.: 742695-60-9HR2-18 is a biological active peptide， with inhibition of SARS-CoV penetration into cells.
-
Tipranavir-d5
0 ImagesCat. No.: HY-15148S2CAS No.: 1126619-17-7Synonyms: PNU-140690-d5Tipranavir-d5 (PNU-140690-d5) is the deuterium labeled Tipranavir (HY-15148). Tipranavir (PNU-140690) inhibits the enzymatic activity and dimerization of HIV-1 protease, exerts potent activity against multi-protease inhibitor (PI)-resistant HIV-1 isolates with IC50s of 66-410 nM. Tipranavir inhibits SARS-CoV-2 3CLpro activity.
-
TO-195 (hydrochlorid)
0 ImagesCat. No.: HY-19195CAS No.: 151328-91-5TO-195 hydrochlorid is a protease inhibitor targeting severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2). TO-195 hydrochlorid is promising for research of coronavirus disease 2019 (COVID-19).
-
(rel)-Lopinavir-d8
0 ImagesCat. No.: HY-14588SCAS No.: 1322625-54-6Synonyms: (rel)-ABT-378-d8(rel)-Lopinavir-d8 ((rel)-ABT-378-d8) is the deuterium labeled Lopinavir (HY-14588). Lopinavir (ABT-378) is a highly potent, selective peptidomimetic inhibitor of the HIV-1 protease, with Kis of 1.3 to 3.6 pM for wild-type and mutant HIV protease. Lopinavir acts by arresting maturation of HIV-1 thereby blocking its infectivity. Lopinavir is also a SARS-CoV 3CLpro inhibitor with an IC50 of 14.2 μM.
-
DHODH-IN-31
0 ImagesCat. No.: HY-178156Purity: 99.55%DHODH-IN-31 is a human dihydroorotate dehydrogenase (DHODH) inhibitor with an IC50 of 0.59 μM. DHODH-IN-31 exhibits antiviral activity. DHODH-IN-31 can be used for the research of infection, such as SARS-CoV-2.
-
S1b3inL1
0 ImagesCat. No.: HY-P10855CAS No.: 3027437-21-1
-
Binifibrate
0 ImagesCat. No.: HY-116977CAS No.: 69047-39-8Binifibrate is an active compound and has a beneficial effect on lipoprotein metabolism. Binifibrate can be used for the research of hyperlipidemia.
-
SARS-CoV-2-IN-61
0 ImagesCat. No.: HY-155308CAS No.: 3044004-40-9SARS-CoV-2-IN-61 (compound 8i) is a SARS CoV-2 PLpro inhibitor with an IC50 of 16 µM. SARS-CoV-2-IN-61 has antiviral activities.
-
Favipiravir-13C15N
0 ImagesCat. No.: HY-14768SSynonyms: T-705-13C15NFavipiravir-13C15N (T-705-13C15N) is 13C and 15N labeled Favipiravir. Favipiravir (T-705) is a potent viral RNA polymerase inhibitor, it is phosphoribosylated by cellular enzymes to its active form, Favipiravir-ribofuranosyl-5′-triphosphate (RTP). Favipiravir-RTP inhibits the influenza viral RNA-dependent RNA polymerase (RdRP) activity with an IC50 of 341 nM.
-
SCR007
0 ImagesCat. No.: HY-178137CAS No.: 2409183-72-6SCR007 is a synthetic carbohydrate receptor (SCR) with broad-spectrum antiviral activity. SCR007 inhibits the entry of enveloped viruses across multiple families (Coronaviridae: SARS-CoV-1, SARS-CoV-2, MERS-CoV; Filoviridae: EBOV, MARV; Paramyxoviridae: NiV, HeV) and the glycosylated nonenveloped rotavirus. SCR007 binds viral envelope N-glycans, blocking viral binding to host cells or both binding and membrane fusion. SCR007 exerts prophylactic effects in hACE2 mice infected with SARS-CoV-2. SCR007 can be used for the study and prevention of enveloped virus pandemics.
-
Antiviral agent 25
0 ImagesCat. No.: HY-152589CAS No.: 2761367-25-1Antiviral agent 25 (compound 6g) is a new non-peptide analog covalent inhibitor of SARS-CoV-2 3CLpro. Antiviral agent 25 has a strong inhibitory effect on SARS-CoV-2 3CLpro and SARS-CoV-2 PLpro with IC50 values of 0.118 µM, 0.448 µM, respectively. Antiviral agent 25 has antiviral effect on SARS-CoV-2 with an EC50 value of 7.249 µM.
-
XR8-69
0 ImagesCat. No.: HY-139892CAS No.: 2817811-10-0XR8-69 is a SARS-CoV-2 PLpro inhibitor that shows low micromolar antiviral potency in SARS-CoV-2-infected human cells.
-
Anti-SARS-CoV-2 S protein Antibody (RBD epitope A, SARS2-01)
0 ImagesCat. No.: HY-P990815Anti-SARS-CoV-2 S protein Antibody (RBD epitope A, SARS2-01) is a mouse-derived IgG1 κ type antibody inhibitor, targeting to SARS-CoV-2 S protein. Anti-SARS-CoV-2 S protein Antibody (RBD epitope A, SARS2-01) reacts with the receptor binding domain (RBD) epitope A in the spike (S) protein of SARS-CoV-2 (Severe Acute Respiratory Syndrome Coronavirus 2). Anti-SARS-CoV-2 S protein Antibody (RBD epitope A, SARS2-01) can block the binding of the SARS-CoV-2 S protein to angiotensin-converting enzyme 2 (ACE2). Anti-SARS-CoV-2 S protein Antibody (RBD epitope A, SARS2-01) can be used for the research of SARS-CoV-2 infection.
-
SARS-CoV-2-IN-40
0 ImagesCat. No.: HY-149304CAS No.: 2984557-53-9SARS-CoV-2-IN-40 (Compound 19) is a SARS-CoV-2 inhibitor. SARS-CoV-2-IN-40 inhibits SARS-CoV-2 BA.1 and BA.5 variant infection of Calu3 lung cells, with IC50s of 100 nM and 160 nM respectively.
-
AVI-4206
0 ImagesCat. No.: HY-175461CAS No.: 3105041-48-0
-
GRL-190-21
0 ImagesCat. No.: HY-162229CAS No.: 2755957-14-1GRL-190-21 (compound 5e) is an inhibitor for SARS-Cov-2-Mpro with a Ki of 0.04 nM and exhibits antiviral activity in VeroE6 cells with EC50 of 0.26 μM. GRL-190-21 reduces the infectivity, replication, and cytopathic effect of SARS-CoV-2 without significant toxicity.
-
SARS-CoV-2 Mpro-IN-45
0 ImagesCat. No.: HY-176211CAS No.: 2992608-40-7SARS-CoV-2 Mpro-IN-45 (compound 28f) is an orally active Mpro inhibitor with IC50 values of 0.12 and 0.16 μM for HCoV-OC43 Mpro and SARS-CoV-2 Mpro, respectively. SARS-CoV-2 Mpro-IN-45 exhibits antiviral activity.
